• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ionis Pharmaceuticals (IONS) Stock Slips As Revenue Drops And Losses Return

    Simply Wall St·07/30/2026 23:34:18
    Listen to the news

    Ionis Pharmaceuticals stock slipped about 1.4% today and sits near US$53 after a tough few months that left shares down roughly one third over 30 and 90 days. The price reaction looks modest next to the earnings headline. Ionis delivered Q2 revenue of US$268m and highlighted a cash balance of US$2.1b, which gives the company room to keep funding its pipeline.

    Short term traders are focused on the ongoing loss per share in this quarter. Longer term investors are weighing that against full year revenue guidance of US$875m to US$900m and the multi year path to breakeven.

    Is Ionis Pharmaceuticals at US$53 a deep value opportunity, or is the wide gap to the DCF estimate sending a false signal for NasdaqGS:IONS? See how the earnings profile lines up in our valuation analysis for Ionis Pharmaceuticals.

    Q2 2026 Earnings Summary

    • Revenue (Q2 2026 vs. Q2 2025): US$268 million vs. US$452.049 million (revenue declined about 41%)
    • Net Income or Loss (Q2 2026 vs. Q2 2025): loss of US$115 million vs. profit of US$123.551 million (swung from profit to loss)
    • Basic EPS (Q2 2026 vs. Q2 2025): loss of US$0.70 per share vs. earnings of US$0.78 per share (moved from profit to loss)
    • Products Launched (Q2 2026 vs. Q2 2025): 1 product launched vs. 0 reported launches (pipeline execution continued at a measured pace)

    Prefer clear visuals instead of another wall of dense financial text? Get a full picture of Ionis Pharmaceuticals' valuation setup in a clean, chart based format with the company report for Ionis Pharmaceuticals.

    NasdaqGS:IONS Trailing 12-Month Earnings & Revenue History as at Jul 2026
    NasdaqGS:IONS Trailing 12-Month Earnings & Revenue History as at Jul 2026

    Ionis Bull Case Hinges On Execution Milestones, Not Hype

    The bullish story around Ionis Pharmaceuticals is that a growing portfolio of launched drugs and late stage assets can steadily improve revenue and margins. The latest quarter shows some of those building blocks in place. Management kept full year revenue guidance at US$875m to US$900m and reiterated product targets for TRYNGOLZA and DAWNZERA, which points to confidence in commercial uptake despite recent stock weakness.

    Key operational milestones have been hit rather than just promised. TRYNGOLZA is approved for severe hypertriglyceridemia, is in market with prescriptions starting on the approval day, and has day one patient access plus payer engagement underway. DAWNZERA is contributing US$42m in first half sales with Q2 growth versus Q1. On the pipeline side, completion of Phase 3 REVEAL enrollment in Angelman syndrome and multiple 2026 regulatory decisions for zilganersen and bepirovirsen keep the multi product launch narrative grounded in concrete progress.

    Compare Ionis Pharmaceuticals' execution milestones with how Wall Street is reacting to the latest earnings by checking whether analyst targets are keeping up with the story in the consensus price target analysis for Ionis Pharmaceuticals.

    Ionis Bear Case: Losses, Setbacks And Concentration Risk

    The bearish view on Ionis Pharmaceuticals is that high spend, partner dependence and clinical setbacks could keep losses entrenched and expose the stock to further disappointments. This quarter gives that argument real support. Revenue fell sharply year on year and the company swung from a profit of US$123.6m to a loss of US$115m, which fits concerns about volatile, “lumpy” partner income and elevated operating costs during multiple launches.

    Pipeline risk also showed up in hard form. The failed CARDIO TTRansform cardiomyopathy trial for WAINUA and Roche’s Huntington’s disease discontinuations removed two potential long term growth legs and validated worries about concentration in a few high impact programs. TRYNGOLZA and DAWNZERA are progressing, but TRYNGOLZA sales of US$5m in Q2 after a price reset keep questions open on pricing pressure and the pace of payer coverage. Reaffirmed guidance points to resilience, yet several bear case milestones clearly went the wrong way.

    With Ionis Pharmaceuticals still loss making after five years and relying on a US$2.1b cash balance to fund its pipeline, you may want to verify the real runway and liquidity pressure in our financial health analysis of Ionis Pharmaceuticals stock.

    Stay Ahead Of Your Next Move

    If Ionis Pharmaceuticals is now on your radar after the sharp revenue swing and updated guidance, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot a potential entry that fits your plan. Once you own it or any other stock, keep your decisions clear with the Portfolio Command Center that cuts through noise and highlights the updates that matter most. For a longer term view, use the Community to see how other investors are thinking about earnings quality, pipeline risk and valuation. By surfacing hidden catalysts and risks early, Simply Wall St helps you act with confidence and stay a step ahead of the market.

    Seeking Alternatives Beyond Ionis Pharmaceuticals?

    Fresh ideas move first. Some stocks are building quiet momentum while others risk getting caught after the breakout. Scan under the radar for now, before the edge drops away, and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.